B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence
- 1 May 2008
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 179 (5) , 1954-1960
Abstract
Despite tremendous gains in improving prognosis, 10% of patients with Wilms tumor will ultimately experience disease recurrence. The identification of novel prognostic markers and tumor associated targets for patients at risk could enable clinicians to treat recurrences more aggressively and, thus, optimize outcomes. We have previously shown that tumor expression of the T cell coregulatory ligand B7-H1 portends a poor prognosis for adults with renal cell carcinoma and represents a promising target to improve therapy. We hypothesize that this finding may be true for Wilms tumor. We identified 81 patients with Wilms tumor treated at 1 institution between 1968 and 2004. Histopathological features, including Wilms tumor B7-H1 expression, were correlated with clinical observations and outcome. Tumor recurrences were noted in 22% of patients with Wilms tumor and 14% died. B7-H1 was expressed in 11 tumors (14%) and was more likely to occur in anaplastic Wilms tumor (p = 0.03). Tumor B7-H1 expression was associated with a 2.7-fold increased risk of recurrence, although this difference did not achieve statistical significance (p = 0.06). However, in favorable histology tumors B7-H1 expression was associated with a 3.7-fold increased risk of recurrence (p = 0.03). B7-H1 is expressed by Wilms tumor, correlates with tumor biology and is associated with an increased risk of recurrence in patients with favorable histology tumors. B7-H1 may prove useful in identifying high risk patients who could benefit from more aggressive initial treatment regimens, and may represent a promising therapeutic target. Multi-institutional studies to elucidate the role of B7-H1 in the treatment of Wilms tumor are warranted.Keywords
This publication has 17 references indexed in Scilit:
- Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor StudyJournal of Clinical Oncology, 2006
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-upCancer Research, 2006
- B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinomaUrology, 2005
- END STAGE RENAL DISEASE IN PATIENTS WITH WILMS TUMOR: RESULTS FROM THE NATIONAL WILMS TUMOR STUDY GROUP AND THE UNITED STATES RENAL DATA SYSTEMJournal of Urology, 2005
- Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetProceedings of the National Academy of Sciences, 2004
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunityNature Medicine, 2003
- Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Controversies and advances in the management of Wilms' tumourArchives of Disease in Childhood, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Wilms tumorCA: A Cancer Journal for Clinicians, 1996